Evidence map›Paper›PMID 33100053›Full record

ArticleDrug delivery2020

A sustained dual drug delivery system for proliferative vitreoretinopathy.

Ying Xiao, Kyung Seek Choi, David Warther, Kristyn Huffman, Stephanie Landeros, William R Freeman, Michael J Sailor, Lingyun Cheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Therapeutic Applications of the CRISPR-Cas System.Bioengineering (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ying XiaoDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.
Kyung Seek ChoiDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.
David WartherDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA, USA.
Kristyn HuffmanDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.
Stephanie LanderosDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.
William R FreemanDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.
Michael J SailorDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA, USA.
Lingyun ChengDepartment of Ophthalmology, Jacobs Retina Center at Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.
University of California, San Diego · US

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Porous Silicon Particles for Sustained Intravitreal Drug DeliveryR01EY020617 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHENG, LINGYUN · 2011 to 2015
$2.6M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY020617
6 · The paper itself

Abstract

Proliferative vitreoretinopathy (PVR) is a significant threat for vision recovery from retinal detachment or ocular trauma. Currently, no approved pharmacological intervention to prevent PVR. Daunorubicin (DNR) and dexamethasone (DEX) were sequentially loaded into oxidized porous silicon (pSiO

Indexed as

AnimalsDaunorubicinDelayed-Action PreparationsDexamethasoneDrug Delivery SystemsIntravitreal InjectionsPorosityRabbitsRetinaRetinal DetachmentSiliconVitreoretinopathy, ProliferativeVitreous BodyDaunorubicinDelayed-Action PreparationsDexamethasoneSilicondaunorubicindexamethasoneDual drug delivery systemproliferative vitreoretinopathy (PVR)rabbit retinal detachment model

Identifiers

PMID33100053
PMCPMC7594716
OpenAlexW3094620047

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.